HMG vs Kisspeptin-10
Human menopausal gonadotropin is a urinary-derived preparation carrying both follicle-stimulating hormone and luteinising hormone activity, approved for decades and used for ovarian stimulation in IVF and ICSI, for ovulation induction, and in combined gonadotropin regimens that induce spermatogenesis in male hypogonadotropic hypogonadism. Kisspeptin-10 is the C-terminal decapeptide of the KISS1 gene product and an agonist at the kisspeptin receptor, acting on the hypothalamus several steps upstream of the pituitary. The two therefore work on the same reproductive axis but at opposite ends: one replaces the pituitary output directly at the gonad, the other attempts to restart the signal that drives that output. No study has administered both compounds within one design, and the human kisspeptin trigger trials in IVF stimulated participants with recombinant FSH rather than with menotropins. The publications that engage both are case reports, cohorts and reviews in which kisspeptin appears as the upstream biology and menotropins as the treatment.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No published study has administered human menopausal gonadotropin and kisspeptin-10 to the same subjects, in humans or in animals, and no trial has randomised participants between them. The full texts of the phase 2 kisspeptin trigger trials in IVF record recombinant FSH as the stimulation drug, so even the setting in which the two might plausibly have met does not contain a co-administration study. What the literature does contain is a set of publications in which the two sit on either side of the same clinical problem. Breuer and colleagues described three siblings with a novel severe splice-site mutation in the kisspeptin receptor gene, one of whom responded to combined chorionic gonadotropin and menopausal gonadotropin therapy while his testes remained small. Hao and colleagues treated 122 men with congenital hypogonadotropic hypogonadism with combined chorionic and menopausal gonadotropin and reported kisspeptin receptor mutations among the causal genes identified in the cohort. Taniguchi and colleagues measured kisspeptin in follicular fluid and plasma in patients stimulated with recombinant FSH and menopausal gonadotropin, and found follicular fluid concentrations higher than plasma and associated with oestradiol and with the number of mature oocytes. The remainder are reviews of hypogonadotropic hypogonadism, hypothalamic amenorrhoea and ovarian hyperstimulation syndrome that describe kisspeptin as investigational upstream physiology and menotropins as established downstream therapy.
The 10 publications that cover both
- 01Case report2012
A novel severe N-terminal splice site KISS1R gene mutation causes hypogonadotropic hypogonadism but enables a normal development of neonatal external genitalia
Breuer O, et al. · European Journal of Endocrinology · three siblings from a consanguineous family with isolated hypogonadotropic hypogonadism, with homozygosity mapping, KISS1R sequencing and RNA expression analysis
A novel homozygous splice-site mutation at the acceptor site of intron 1 of the kisspeptin receptor gene was identified in the affected siblings, producing exon skipping and a premature stop codon. The sisters' oestradiol failed to rise in response to chorionic gonadotropin, while the brother's testosterone responded to combined chorionic gonadotropin and human menopausal gonadotropin therapy although his testes remained small. The authors suggested the subnormal gonadal response implicated a direct role for the receptor in gonadal function.
- 02Human clinical2020
Gonadotropin treatment for male partial congenital hypogonadotropic hypogonadism in Chinese patients
Hao M, et al. · Asian Journal of Andrology · retrospective study of 587 patients with congenital hypogonadotropic hypogonadism, of whom 122 noncryptorchid compliant patients received combined chorionic and menopausal gonadotropin and were monitored for 24 months
Patients with partial congenital hypogonadotropic hypogonadism achieved a higher spermatogenesis rate than those with the complete form (92.3% versus 74.7%) and took less time to begin producing sperm (median 11.7 versus 17.8 months). Genetic screening of the probands identified kisspeptin receptor mutations among the causal genes in the complete disease group, placing kisspeptin signalling failure upstream of the gonadotropin therapy the cohort received.
- 03Human clinical2017
Intra-follicular kisspeptin levels are related to oocyte maturation and gonadal hormones in patients who are undergoing assisted reproductive technology
Taniguchi Y, et al. · Reproductive Medicine and Biology · observational study of 39 women aged 24-40 undergoing oocyte retrieval, with kisspeptin measured in 65 follicular fluid samples from 30 patients and in plasma from 14, following stimulation with recombinant FSH and human menopausal gonadotrophin
Follicular fluid kisspeptin was significantly higher than plasma kisspeptin and was positively associated with follicular fluid and serum oestradiol and with the number of mature oocytes. Plasma kisspeptin reached its maximum on the day of ovum pick-up and on the day of embryo transfer. The authors concluded that plasma kisspeptin concentration was affected by ovarian stimulation, in which menopausal gonadotrophin formed part of the regimen.
- 04Review2025
Hypogonadotropic hypogonadism as a cause of NOA and its treatment
Salvio G, et al. · Asian Journal of Andrology · narrative review of congenital and acquired hypogonadotropic hypogonadism as a correctable cause of non-obstructive azoospermia
The review described the kisspeptin-neurokinin-dynorphin system as the principal modulator of the gonadotropin-releasing hormone pulse generator and kisspeptin as capable of stimulating pituitary gonadotrophs directly. Separately it listed menotropin, urinary FSH and recombinant FSH as the available FSH preparations for induction of spermatogenesis, and reported that gonadotropin replacement corrected the condition in around three quarters of cases while a significant minority did not respond adequately.
- 05Review2020
Current understanding of hypothalamic amenorrhoea
Roberts RE, et al. · Therapeutic Advances in Endocrinology and Metabolism · narrative review of the mechanisms, clinical management and emerging therapies of functional hypothalamic amenorrhoea
The review described kisspeptin signalling as the common intermediate acting downstream of leptin and other neuromodulatory inputs to modulate gonadotropin-releasing hormone activity, and listed kisspeptin among emerging therapies for the condition. In the treatment section it recorded that highly purified human menopausal gonadotrophin preparations provide sufficient luteinising hormone activity for ovulation induction in this patient group.
- 06Systematic review2023
Interventions to prevent or reduce the incidence and severity of ovarian hyperstimulation syndrome: a systematic umbrella review of the best clinical evidence
Palomba S, et al. · Reproductive Biology and Endocrinology · systematic umbrella review of systematic reviews with meta-analysis covering interventions that modify ovarian hyperstimulation syndrome risk
The review described menotropin, the urinary-derived preparation containing luteinising hormone and follicle-stimulating hormone activity, as the first generation of gonadotropins used for stimulation, and assessed gonadotropin choice among the interventions capable of modifying syndrome risk. Kisspeptin was listed among promising interventions that could not be analysed because meta-analytical evidence supporting it did not yet exist.
- 07Systematic review2023
Beyond the Umbrella: A Systematic Review of the Interventions for the Prevention of and Reduction in the Incidence and Severity of Ovarian Hyperstimulation Syndrome in Patients Who Undergo In Vitro Fertilization Treatments
Palomba S, et al. · International Journal of Molecular Sciences · systematic review of interventions for prevention and reduction of ovarian hyperstimulation syndrome not covered by meta-analytical evidence, with gonadotropin preparations tabulated alongside them
The review reported that only one phase 2 randomised trial, in sixty women at high risk of the syndrome, had examined kisspeptin-54 as a trigger of oocyte maturation, and that no moderate, severe or critical event occurred in it. The authors recorded that the small number of trials reflected kisspeptin not being a licensed medicine, in contrast to the gonadotropin preparations, including human menopausal gonadotrophin, tabulated as established stimulation options.
- 08Review2026
Epidemiology, Etiopathogenesis, Diagnosis, and Treatment of Male Infertility-Current Trends and Future Directions: A Narrative Review
Wani FA · Medicina · narrative review of the epidemiology, causes, diagnosis and treatment of male infertility
The review set out the pharmacological options for hormonal treatment, recording that chorionic gonadotropin mimics luteinising hormone activity, recombinant FSH provides follicle-stimulating activity, and human menopausal gonadotropin combines both. In the emerging-therapy section it described kisspeptin therapy as a gonadotropin-releasing hormone secretagogue that restores pulsatile secretion in hypogonadotropic hypogonadism, with preliminary studies described as promising, and noted that kisspeptin-10 is a potent stimulator of luteinising hormone in men.
- 09Review2024
The prospect of artificial intelligence to personalize assisted reproductive technology
Hanassab S, et al. · npj Digital Medicine · review of machine-learning approaches applied to personalisation of assisted reproductive technology, including the stimulation and trigger datasets used to train them
The review described a modelling dataset in which 87% of stimulation cycles included a menotropin preparation alongside pure FSH for luteinising hormone activity, and 13% used FSH alone. Among the endocrine models tabulated it included work on the requirements for oocyte maturation following chorionic gonadotropin, gonadotropin-releasing hormone agonist and kisspeptin-54 triggers, placing the two compounds at different points of the same treatment cycle.
- 10Review2022
Central and Local Modulators of Reproduction and Fertility: An Update
Meccariello R · International Journal of Molecular Sciences · editorial review summarising a collection of studies on central and local modulators of reproduction
The review described the kisspeptin system as the main gatekeeper of gonadotropin-releasing hormone neurons in mammals, and summarised work reporting impaired kisspeptin signalling and reduced ovulation in a mutant fish model, and characterisation of the kisspeptin system in the testis. It also summarised a study comparing three controlled ovarian stimulation protocols, urinary FSH, recombinant FSH and human menopausal gonadotropin, in cumulus cells from 42 normal-responder women.
Side by side.
| HMG | Kisspeptin-10 | |
|---|---|---|
| Evidence maturity | Approved drug | Early clinical |
| Studies cited here | 15 | 16 |
| Published 2023 or later | 11 | 12 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | Not a single peptide. A urinary-derived preparation of glycoprotein gonadotropins extracted from postmenopausal urine, carrying follicle-stimulating and luteinising hormone activity, the latter contributed substantially by chorionic gonadotropin retained during purification. | A synthetic decapeptide corresponding to the C-terminal fragment of the KISS1 gene product, an endogenous hypothalamic neuropeptide, sometimes recorded as human metastin 45-54. |
| Mechanism as described in the literature | Acts at the gonad, downstream of the whole hypothalamic-pituitary system, so its effect does not depend on hypothalamic or pituitary function being intact. | Acts at the kisspeptin receptor on gonadotropin-releasing hormone neurons and on pituitary gonadotrophs, upstream of the pituitary output, so any effect depends on a responsive axis below it. |
| Size of the evidence base | Large and randomised. A 2026 Cochrane update, several 2025-2026 meta-analyses, an equivalence trial in 620 predicted high responders and a meta-analysis of 28 studies including 7,553 women all address the same clinical question. | Small and mostly acute. Human administration studies have been single-centre experiments in healthy volunteers and small patient groups, largely from one research group, and much of the clinical work used the longer isoform kisspeptin-54 rather than the decapeptide. |
| Best-characterised finding | Live birth and clinical pregnancy were probably higher, and ovarian hyperstimulation syndrome probably lower, than with recombinant FSH in the Cochrane comparison, with other pooled analyses finding little to no difference in live birth alongside a more favourable syndrome profile. | A dose-related rise in gonadotropins after administration, sexually dimorphic in humans and shorter-lived than the response to kisspeptin-54 in a direct comparison of the two isoforms with gonadotropin-releasing hormone. |
| Human data | Decades of randomised controlled trials with pregnancy and live birth endpoints, plus consensus documents on where luteinising hormone activity is worth adding. | No trial has reported live birth, pregnancy or sustained symptomatic improvement with kisspeptin-10 itself, and the trigger trials that reached clinical endpoints used kisspeptin-54. |
| Evidence maturity | Approved medicine with a mature comparative literature, where the open questions concern which patient subgroups benefit rather than whether the drug works. | Early clinical. Human work is dominated by short administration experiments establishing that the axis responds, with long-term safety data absent. |
| Regulatory status | Approved and marketed as menotropins in major jurisdictions for ovarian stimulation and ovulation induction, and used in combined regimens for male hypogonadotropic hypogonadism. | Investigational everywhere. No kisspeptin peptide is approved as a medicine in any major jurisdiction, and one 2026 review of peptide availability in sexual medicine recorded kisspeptin on the United States regulator's category 2 list of bulk drug substances with limited safety information. |
| Basis of most marketing claims | Claims track approved fertility indications, though the choice between preparations is contested and the pooled differences in live birth are small and protocol-dependent. | Claims extend acute hormone-release experiments in healthy volunteers to fertility, libido and hormonal optimisation outcomes that no kisspeptin-10 trial has measured. |
And what it does not.
The two compounds have never been tested against each other, and the reason is structural rather than accidental: they occupy different levels of the same axis and answer different clinical questions. Menotropins replace gonadotropin activity at the gonad and have been examined in randomised trials with live birth endpoints for decades, where the remaining disagreements concern which preparation suits which responder phenotype rather than whether gonadotropin therapy works. Kisspeptin-10 acts on the hypothalamus and has been studied almost entirely as an acute probe of whether the reproductive axis responds, in small single-centre experiments, with much of the clinical work carried out using kisspeptin-54 instead. The publications that engage both describe kisspeptin as the upstream biology whose failure causes hypogonadotropic hypogonadism and menotropins as the treatment given once it has failed. Nothing in the literature establishes that kisspeptin-10 can substitute for gonadotropin therapy, and nothing establishes a fertility, libido or hormonal outcome for kisspeptin-10 in people.
Common questions.
- Has any study given human menopausal gonadotropin and kisspeptin-10 together?
No. Searches of PubMed and Europe PMC returned no study, human or animal, that administered both. The point at which they might have met is IVF, where kisspeptin has been tested as a trigger of oocyte maturation, but the full texts of those phase 2 trials record recombinant FSH as the stimulation drug rather than menotropins. The publications that name both are case reports, cohorts and reviews in which kisspeptin appears as upstream physiology and menopausal gonadotropin as the treatment administered.
- What does the kisspeptin receptor mutation literature show about gonadotropin therapy?
It shows the two working in sequence rather than in competition. Loss-of-function mutations in the kisspeptin receptor cause normosmic hypogonadotropic hypogonadism, and patients carrying them have been treated with combined chorionic and menopausal gonadotropin. In one family, a brother with a severe splice-site mutation showed a testosterone response to that regimen while his testes remained small; in a larger Chinese cohort treated with the same combination, receptor mutations were among the causal genes identified. Gonadotropin therapy bypasses the defect rather than correcting it.
- Is kisspeptin-10 the same peptide used in the IVF trigger trials?
Not in most cases. The trigger trials that reported oocyte maturation and clinical outcomes used kisspeptin-54, the longer isoform. A direct comparison in healthy men found that both isoforms stimulated gonadotropin secretion but that kisspeptin-54 produced a more prolonged response than the shorter kisspeptin-10. Reviews of the field consistently distinguish the two, and the evidence gaps recorded for kisspeptin-10 include the fact that much of the human clinical work was conducted with the longer form.
- Why is menopausal gonadotropin still used when recombinant preparations exist?
Because the comparison has not resolved in one direction. A 2026 Cochrane update reported that live birth and clinical pregnancy were probably lower with recombinant FSH than with menopausal gonadotropin preparations and that ovarian hyperstimulation syndrome was probably higher, while other 2026 meta-analyses found little to no difference in live birth alongside differing oocyte yields. A meta-analysis of 28 studies concluded the differences were small enough that availability, cost and patient preference were reasonable grounds for choosing.
- Could kisspeptin ever replace gonadotropin stimulation?
The published rationale is narrower than that. Kisspeptin has been investigated as a trigger of final oocyte maturation, not as a replacement for the stimulation phase, and the interest in it rests on the possibility of a more physiological luteinising hormone surge with a lower risk of ovarian hyperstimulation syndrome. Reviews of syndrome prevention list it among promising interventions that could not yet be analysed because meta-analytical evidence did not exist. No published work proposes it as a substitute for gonadotropin therapy at the gonad.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.